Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Cnpharm Co. Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. Each matter is associated with a distinct examiner and a distinct art unit, so the portfolio’s current activity spans separate examination channels.
YOUNGBLOOD, WILLIAM JUSTIN is the busiest examiner, with 1 pending matter. The even examiner distribution limits the value of a single-examiner strategy and supports individualized review of each action, claim set, and art-unit context.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
| KAUCHER, MARK S | 1 | 72.5% | +14.0% |
| KIM, DANIELLE A | 1 | 36.6% | +51.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18844613 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PREPARATION METHOD THEREFOR | YOUNGBLOOD, WILLIAM JUSTIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17428111 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KIM, DANIELLE A | 53d overdue |
| 18844613 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PREPARATION METHOD THEREFOR | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18587826 | NOVEL CATIONIC POLYPHOSPHAZENE COMPOUND, POLYPHOSPHAZENES-DRUG CONJUGATE COMPOUND AND METHOD FOR PREPARING SAME | KAUCHER, MARK S | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1615 | 1 |
| 1764 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844613 | PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PREPARATION METHOD THEREFOR | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102§112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18649055 | METAL (HYDR) OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | MERCIER, MELISSA S | 1615 | §112Other | Non-Final OA | 13d | Pending | Apr 29, 2024 |
| 18587826 | NOVEL CATIONIC POLYPHOSPHAZENE COMPOUND, POLYPHOSPHAZENES-DRUG CONJUGATE COMPOUND AND METHOD FOR PREPARING SAME | KAUCHER, MARK S | 1764 | §112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 17428111 | METAL (HYDR)OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KIM, DANIELLE A | 1613 | §103 | Final Rejection | 53d overdue | Pending | Aug 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCnpharm Co. Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
William Justin Youngblood has the most, with 1 of Cnpharm Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
